KALA Stock Risk & Deep Value Analysis
KALA BIO Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KALA Stock
We analyzed KALA BIO Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KALA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive investment. Here's what we found.
How Risky Is KALA Stock?
Overall Risk
Aggressive investment
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for KALA?
- âš
Negative clinical trial results for XP-898 (EGR-401)
- âš
Further substantial dilutive financing without significant pipeline progress
- âš
Increased competition in the rare ocular disease space
- âš
Regulatory delays or rejection of XP-898
Unlock KALA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does KALA BIO Inc (KALA) Do?
Market Cap
$10.92M
Sector
Healthcare
Industry
Biotechnology
Employees
38
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Visit KALA BIO Inc WebsiteIs KALA Stock Undervalued?
Unlock the full AI analysis for KALA
Get the complete DVR score, risk analysis, and more
Does KALA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Potentially Expanding
Moat Sources
1 Identified
Highly dependent on successful clinical development, regulatory approval, and robust patent protection for XP-898. If approved, orphan drug designation provides market exclusivity for a limited period.
Moat Erosion Risks
- •Clinical trial failure for XP-898
- •Patent expiry or invalidation of key intellectual property
- •Emergence of superior or faster-to-market competing treatments
KALA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive KALA Stock Higher?
Near-Term (0-6 months)
- •Phase 2/3 XP-898 (EGR-401) clinical trial updates/readouts (expected Q2/Q3 2026)
- •Details of recent significant financing round (if applicable to market cap increase)
Medium-Term (6-18 months)
- •XP-898 (EGR-401) progression to Phase 3 initiation
- •Announcement of strategic partnership or licensing deal for XP-898
- •Updates on additional pipeline asset development
Long-Term (18+ months)
- •XP-898 (EGR-401) regulatory filing and potential approval (2028-2029)
- •Market launch of XP-898 and initial sales data
- •Expansion into other retinal diseases or indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KALA?
- ✓
Positive clinical trial data for XP-898 (EGR-401)
- ✓
Announcement of a significant pharmaceutical partnership or licensing deal
- ✓
Cash runway extended beyond 18 months via non-dilutive means
- ✓
Continued progress of pipeline assets
Bull Case Analysis
See what could go right with Premium
Compare KALA to Similar Stocks
See how KALA BIO Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KALA (KALA BIO Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
